Predictors of viral LRTI after allo-HCT
| Predictor . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | |
| Age, y | 1.00 (0.98-1.02) | .904 | ||
| Sex (female) | 1.01 (0.55-1.81) | .962 | ||
| Underlying disease (leukemia vs other) | 1.38 (0.78-2.49) | .271 | ||
| Conditioning intensity (myeloablative) | 1.00 | — | ||
| Conditioning intensity (reduced intensity) | 1.04 (0.58-1.85) | .904 | ||
| Conditioning intensity (nonmyeloablative) | 0.66 (0.13-2.02) | .509 | ||
| T-cell depletion (ex vivo) | 1.26 (0.71-2.27) | .435 | ||
| Stem cell source (related identical) | 1.00 | — | 1.00 | — |
| Stem cell source (unrelated Identical) | 0.80 (0.37-1.74) | .563 | 0.78 (0.36-1.71) | .524 |
| Stem cell source (nonidentical) | 1.79 (0.79-4.02) | .157 | 1.77 (0.78-3.99) | .172 |
| Stem cell source (cord blood) | 1.36 (0.60-3.05) | .454 | 0.89 (0.38-2.07) | .790 |
| Time to engraftment (≥14 d) | 1.27 (0.65-2.33) | .469 | ||
| Corticosteroid administration* | 2.36 (1.32-4.25) | .004 | 2.33 (1.27-4.32) | .007 |
| Abnormal DLCO (<80% predicted) | 1.10 (0.61-1.94) | .753 | ||
| Abnormal FEV1 (<80% predicted) | 1.09 (0.46-2.23) | .834 | ||
| Abnormal FVC (<80% predicted) | 1.08 (0.46-2.23) | .840 | ||
| Prior β-lactam use | 1.66 (0.78-4.19) | .201 | ||
| Prior fluoroquinolone use | 0.75 (0.39-1.56) | .420 | ||
| Prior metronidazole use | 1.10 (0.49-2.19) | .804 | ||
| Prior vancomycin (IV) use | 1.07 (0.29-9.46) | .935 | ||
| Prior macrolide use | 3.04 (1.11-6.80) | .033 | 2.79 (1.01-6.35) | .049 |
| Butyrate abundance: absent (<0.0001) | 1.00 | — | 1.00 | — |
| Butyrate abundance: low (0.0001-0.01) | 0.90 (0.50-1.61) | .722 | 0.92 (0.51-1.66) | .789 |
| Butyrate abundance: high (>0.01) | 0.20 (0.04-0.61) | .003 | 0.22 (0.04-0.69) | .006 |
| Predictor . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | |
| Age, y | 1.00 (0.98-1.02) | .904 | ||
| Sex (female) | 1.01 (0.55-1.81) | .962 | ||
| Underlying disease (leukemia vs other) | 1.38 (0.78-2.49) | .271 | ||
| Conditioning intensity (myeloablative) | 1.00 | — | ||
| Conditioning intensity (reduced intensity) | 1.04 (0.58-1.85) | .904 | ||
| Conditioning intensity (nonmyeloablative) | 0.66 (0.13-2.02) | .509 | ||
| T-cell depletion (ex vivo) | 1.26 (0.71-2.27) | .435 | ||
| Stem cell source (related identical) | 1.00 | — | 1.00 | — |
| Stem cell source (unrelated Identical) | 0.80 (0.37-1.74) | .563 | 0.78 (0.36-1.71) | .524 |
| Stem cell source (nonidentical) | 1.79 (0.79-4.02) | .157 | 1.77 (0.78-3.99) | .172 |
| Stem cell source (cord blood) | 1.36 (0.60-3.05) | .454 | 0.89 (0.38-2.07) | .790 |
| Time to engraftment (≥14 d) | 1.27 (0.65-2.33) | .469 | ||
| Corticosteroid administration* | 2.36 (1.32-4.25) | .004 | 2.33 (1.27-4.32) | .007 |
| Abnormal DLCO (<80% predicted) | 1.10 (0.61-1.94) | .753 | ||
| Abnormal FEV1 (<80% predicted) | 1.09 (0.46-2.23) | .834 | ||
| Abnormal FVC (<80% predicted) | 1.08 (0.46-2.23) | .840 | ||
| Prior β-lactam use | 1.66 (0.78-4.19) | .201 | ||
| Prior fluoroquinolone use | 0.75 (0.39-1.56) | .420 | ||
| Prior metronidazole use | 1.10 (0.49-2.19) | .804 | ||
| Prior vancomycin (IV) use | 1.07 (0.29-9.46) | .935 | ||
| Prior macrolide use | 3.04 (1.11-6.80) | .033 | 2.79 (1.01-6.35) | .049 |
| Butyrate abundance: absent (<0.0001) | 1.00 | — | 1.00 | — |
| Butyrate abundance: low (0.0001-0.01) | 0.90 (0.50-1.61) | .722 | 0.92 (0.51-1.66) | .789 |
| Butyrate abundance: high (>0.01) | 0.20 (0.04-0.61) | .003 | 0.22 (0.04-0.69) | .006 |
Time-dependent predictor.
CI, confidence interval.